From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||147.7 kg/mol|
|(what is this?)|
Samalizumab is a humanized monoclonal antibody designed for oncology indications.
Samalizumab was developed by Alexion Pharmaceuticals.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|